GTx, Inc. Share Price Nasdaq
Equities
US40052B2079
Biotechnology & Medical Research
Sales 2024 * | 6L 4.75Cr | Sales 2025 * | 7L 5.63Cr | Capitalization | 2.55Cr 212.93Cr |
---|---|---|---|---|---|
Net income 2024 * | -3.5Cr -292.11Cr | Net income 2025 * | -4.8Cr -400.61Cr | EV / Sales 2024 * | 44.8 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 37.8 x |
P/E ratio 2024 * |
-0.72
x | P/E ratio 2025 * |
-1.02
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.77% |
Latest transcript on GTx, Inc.
Managers | Title | Age | Since |
---|---|---|---|
James Breitmeyer
FOU | Founder | 70 | 01/97/01 |
Richard Vincent
DFI | Director of Finance/CFO | 61 | 01/17/01 |
Salim Yazji
CTO | Chief Tech/Sci/R&D Officer | 55 | 17/21/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Hale
FOU | Founder | 75 | 01/97/01 |
Dan Kisner
BRD | Director/Board Member | 77 | 07/19/07 |
Rosemary Mazanet
BRD | Director/Board Member | 67 | 27/21/27 |
1st Jan change | Capi. | |
---|---|---|
+29.03% | 4.92TCr | |
-0.10% | 4.21TCr | |
+46.85% | 4.04TCr | |
-5.26% | 2.89TCr | |
+11.48% | 2.61TCr | |
-22.74% | 1.87TCr | |
+9.06% | 1.33TCr | |
+30.01% | 1.23TCr | |
-1.51% | 1.2TCr |